Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Challenges and importance of long-term treatment for newly diagnosed multiple myeloma patients; community-based trial data

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
video not found
This video is restricted to members who are registered with ecancer as a healthcare professional
Please login or register for free to confirm your details.
Published: 09.12.19
Views: 931

Prof Sagar Lonial, Prof Meral Beksaç, Dr Robert Rifkin

Prof Sagar Lonial (Emory University, Atlanta, USA), Prof Meral Beksaç (University of Ankara, Ankara, Turkey) and Dr Robert Rifkin (Rocky Mountain Cancer Centers, Denver, USA) discuss the results from the US MM-6 study, along with the challenges associated with the long-term treatment of patients with newly diagnosed multiple myeloma (NDMM). This study was conducted in community-based oncology settings, where real-world treatment patterns were observed.

Dr Rifkin gives an overview of the US MM-6 study and explains the unique design of the study, which evaluated the transition from bortezomib to ixazomib in these patients. He discusses the main results from this study, which assessed patient quality of life and mentions that this treatment was well-tolerated and achieved a compliance rate of more than 90 percent.

Prof Beksaç highlights the current treatment landscape of these patients in Europe and the panel discuss some of the treatment challenges – especially in the older and frail population.

The panel emphasise that the use of real-world data presents an accurate reflection of this patient population and similar studies in this area are needed. Dr Rifkin mentions that this study will be expanded in the future, with the addition of European centres.

This programme has been supported by an unrestricted educational grant from Takeda.

Background of the US MM-6 study
Results of the US MM-6 study
Tolerability and safety of the IRd regimen
Implications of the real-world study design
Current treatment landscape in Europe
Challenges of long-term treatment
Evaluating quality of life data
Challenges in the management of MM patients


Related videos

follow us

SIOG metastatic renal cell carcinoma

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation